https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2003-02-15 / J. Immunol. 2003 Feb;170(4):1980-6
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2003-02-15 / J. Immunol. 2003 Feb;170(4):1980-62003-02-15 00:00:002019-02-15 08:50:31Prevention of spontaneous breast carcinoma by prophylactic vaccination with dendritic/tumor fusion cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2003-02-15 / J. Immunol. 2003 Feb;170(4):1814-21
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2003-02-15 / J. Immunol. 2003 Feb;170(4):1814-212003-02-15 00:00:002020-06-23 09:42:47TNF-related apoptosis-inducing ligand mediates tumoricidal activity of human monocytes stimulated by Newcastle disease virus
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2003-02-06 / Cancer Immunol. Immunother. 2003 Mar;52(3):155-61
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2003-02-06 / Cancer Immunol. Immunother. 2003 Mar;52(3):155-612003-02-06 00:00:002019-02-15 09:13:27A phase I study of autologous dendritic cell-based immunotherapy for patients with unresectable primary liver cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2003-02-01 / Expert Rev Anticancer Ther 2003 Feb;3(1):1-3
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2003-02-01 / Expert Rev Anticancer Ther 2003 Feb;3(1):1-32003-02-01 00:00:002019-02-15 08:44:50Dendritic cell therapy of cancer: can it fulfill its promise?
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2003-02-01 / J Dtsch Dermatol Ges 2003 Feb;1(2):120-5
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2003-02-01 / J Dtsch Dermatol Ges 2003 Feb;1(2):120-52003-02-01 00:00:002019-02-15 09:19:55Intradermal injection of Newcastle disease virus-modified autologous melanoma cell lysate and interleukin-2 for adjuvant treatment of melanoma patients with resectable stage III disease
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2003-02-01 / Clin. Breast Cancer 2003 Feb;3 Suppl 4:S158-63
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2003-02-01 / Clin. Breast Cancer 2003 Feb;3 Suppl 4:S158-632003-02-01 00:00:002019-02-15 08:50:30Fusions of breast cancer and dendritic cells as a novel cancer vaccine
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2003-02-01 / Clin Breast Cancer 2003 Feb;3 Suppl 4:S164-72
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2003-02-01 / Clin Breast Cancer 2003 Feb;3 Suppl 4:S164-722003-02-01 00:00:002003-02-01 00:00:00HER2 dendritic cell vaccines
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2003-01-01 / Clin. Cancer Res. 2003 Jan;9(1):174-80
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2003-01-01 / Clin. Cancer Res. 2003 Jan;9(1):174-802003-01-01 00:00:002020-06-23 09:43:48Influence of adjuvant hormone therapy and chemotherapy on the immune system analysed in the bone marrow of patients with breast cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2003-01-01 / Oncology 2003;65 Suppl 2:76-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2003-01-01 / Oncology 2003;65 Suppl 2:76-92003-01-01 00:00:002003-01-01 00:00:00Ifosfamide with regional hyperthermia in soft-tissue sarcomas
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2003-01-01 / Oncology 2003;64(4):312-21
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2003-01-01 / Oncology 2003;64(4):312-212003-01-01 00:00:002003-01-01 00:00:00A Systemic Hyperthermia Oncologic Working Group trial. Ifosfamide, carboplatin, and etoposide combined with 41.8 degrees C whole-body hyperthermia for metastatic soft tissue sarcoma
